Srividya B. Balachander
0000-0002-4653-0432
Publication & Citation Trends
Publications
0 total
Optimization of α-Fluoro, β-Heteroaryl Acrylamide Warheads for KRASG12C Active-State Inhibition.
Cited by 0
Semantic Scholar
Antileukemia efficacy of the dual BCL2/BCL-XL inhibitor AZD0466 in acute lymphoblastic leukemia preclinical models
Cited by 9
Semantic Scholar
Abstract 6150: AZD0466, a dual BCL-2/XL targeting nanomedicine, is active in small cell lung cancer models
Cited by 0
Semantic Scholar
Quantitative Evaluation of Dendritic Nanoparticles in Mice: Biodistribution Dynamics and Downstream Tumor Efficacy Outcomes.
Cited by 1
Semantic Scholar
A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma OA
Cited by 0
Semantic Scholar
Design and optimisation of dendrimer-conjugated Bcl-2/xL inhibitor, AZD0466, with improved therapeutic index for cancer therapy OA
Cited by 77
Semantic Scholar
Research Topics
Cytokine Signaling Pathways and Interactions
(24)
Mathematical Biology Tumor Growth
(22)
Chronic Myeloid Leukemia Treatments
(8)
RNA Interference and Gene Delivery
(6)
Computational Drug Discovery Methods
(4)
Affiliations
Bristol-Myers Squibb (Germany)
Bristol-Myers Squibb (United States)
AstraZeneca (Brazil)
Bristol-Myers Squibb (Belgium)
Constellation Pharmaceuticals (United States)